NEW YORK – As companies and investigators push closer to validating liquid biopsy tests for cancer screening and early detection, approaches relying on epigenetic and DNA fragment patterns are leading the way, according to both commercial and academic players.
At the American Association for Cancer Research Advances in Liquid Biopsy meeting last month, for example, presenters included commercial firm Grail, which highlighted some of its most recent data on a targeted methylation-based pan-cancer detection assay.